Metabolic healthy obesity is associated with higher incidence of mild decrease estimate glomerular rate in rural
Shasha Yu1, Xiaofan Guo1, Guang Xiao Li2
1Department of Cardiology, First Hospital of China Medical University, Shenyang, 110001, China.
BMC Nephrology
|November 25, 2020
Summary
Metabolic healthy obesity (MHO) increases the risk of reduced kidney function in both men and women. Metabolic abnormal obesity (MAO) is linked to reduced kidney function in men, highlighting the need for kidney monitoring in these populations.
Area of Science:
- Nephrology
- Metabolic Health
- Epidemiology
Background:
- Metabolic healthy obesity (MHO) is linked to lower cardiovascular disease risk but higher risks of metabolic syndrome and diabetes.
- The relationship between MHO, metabolic abnormal obesity (MAO), and kidney function requires further investigation.
Purpose of the Study:
- To determine the prevalence of MHO and MAO at baseline in rural Northeast Chinese adults.
- To analyze changes in obese metabolic phenotypes during follow-up.
- To assess the association between MHO/MAO and the incidence of mildly reduced estimated glomerular filtration rate (eGFR).
Main Methods:
- Utilized the CKD-EPI equation to calculate eGFR for 4903 participants (aged ≥35 years) with baseline eGFR >90 ml/min/1.73 m².
- Collected data through questionnaires, anthropometric measurements, and blood tests at baseline and follow-up.
- Defined mildly reduced eGFR as 60–90 ml/min/1.73 m².
Main Results:
- MHO prevalence was 20.0% (women: 19.0%, men: 21.1%), lower than MAO (24.4%).
- Phenotypic changes occurred in 38.4% of women and 38.9% of men.
- MHO was associated with a higher incidence of mildly reduced eGFR in both women (OR=1.6) and men (OR=1.6). MAO was associated with higher incidence in men (OR=1.7) only.
Conclusions:
- MHO is linked to an increased incidence of mildly reduced eGFR in both sexes.
- MAO shows a specific association with reduced eGFR in men.
- Kidney function monitoring is crucial for individuals with MHO and MAO.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
83
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
83
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
81
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
81
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
118
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
118
01:21Drug Dosing: Obese Patients
91
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
91
01:24Obesity
950
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
950
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
152
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
152